Brief: HLS Therapeutics Inc Reports Q3 Net Loss $0.05 Per Common Share

HLS Therapeutics

05/11/2020 12:39

Nov 5 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES Q3 2020 FINANCIAL RESULTS AND
NORMAL
COURSE ISSUER BID
    * HLS THERAPEUTICS INC - QTRLY NET LOSS WAS $0.05 PER COMMON
SHARE
    * HLS THERAPEUTICS INC - QTRLY REVENUE $13.1 MILLION VERSUS
$13.4
MILLION
    * HLS THERAPEUTICS INC - NORMAL COURSE ISSUER BID BECOMES
EFFECTIVE NOVEMBER 9, 2020

Source text for Eikon:  ID:nCNWF6tbga 
Further company coverage:  HLS.TO